Ovarian cancer trials in Poland

In Poland 29 Also abroad 795

29 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Where
Bialystok, Gdansk, Kielce, Poznan, Szczecin, Warsaw
Age
18 years and over
People
770 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00
Phase 3Taking people
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Where
Bialystok, Poznan, Siedlce, Szczecin, Warsaw
Age
18 years and over
People
900 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00
Phase 3Taking people
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Where
Gdansk, Krakow, Poznan, Siedlce, Szczecin
Age
18 years and over
People
420 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500
Phase 3Taking people
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Where
Olsztyn
Age
18 years and over
People
950 worldwide
Run by
AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00
Phase 3Taking people
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Where
Bialystok, Gdansk, Krakow, Poznan, Siedlce
Age
18 years and over
People
1,630 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Where
Bialystok, Gdansk, Gdynia, Poznan, Siedlce, Szczecin
Age
18 years and over
People
688 worldwide
Run by
Genmab
See details and how to joinNCT07564141 · EU 2025-524202-15-00
Phase 3Taking people
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Where
Bialystok, Gdansk, Siedlce
Age
18 years and over
People
270 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00
Phase 3Taking people
Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
Where
Cracow, Lodz, Poznan, Siedlce, Szczecin
Age
18 years and over
People
197 worldwide
Run by
K-Group Beta Inc.
See details and how to join2025-524641-27-00 · EU 2025-524641-27-00
Phase 2Taking people
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Where
Bialystok, Cracow, Gdynia, Poznan, Warsaw
Age
18 years and over
People
310 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT05128825 · EU 2022-502983-19-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Cracow
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Where
Poznan, Siedlce, Szczecin
Age
18 years and over
People
582 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00
Phase 2/3Taking people
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Where
Bialystok, Gdansk, Poznan, Siedlce
Age
18 years and over
People
860 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Cracow, Lodz, Rzeszów, Siedlce, Skorzewo
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
No phaseTaking people
Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions
Where
Zamość
Age
18 years and over
People
500
Run by
Affidea Nu-med Center of Oncological DIagnostics and Therapy
See details and how to joinNCT07883798
No phaseTaking people
Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer
Where
Zamość
Age
18 years and over
People
500
Run by
Affidea Nu-med Center of Oncological DIagnostics and Therapy
See details and how to joinNCT07667192
Phase 3Taking people
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Where
Bialystok, Gdansk, Kielce, Siedlce, Szczecin
Age
18 years and over
People
466 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07214779 · EU 2025-522748-42-00
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Gdansk, Warsaw
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Where
Bialystok, Gdansk, Katowice, Lodz, Lublin, Poznan, Siedlce
Age
18 years and over
People
544 worldwide
Run by
Genmab
See details and how to joinNCT07225270 · EU 2025-522167-15-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Cracow, Gliwice, Warsaw
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 1Taking people
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Where
Cracow, Gdansk, Lodz, Poznan, Warsaw
Age
18 years and over
People
180 worldwide
Run by
Duke Street Bio Ltd
See details and how to joinNCT06458712 · EU 2023-508805-26-00
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Gdansk, Poznan, Warsaw
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
Phase 1Taking people
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
Where
Bydgoszcz, Otwock, Warsaw
Age
18 years and over
People
40
Run by
Molecure S.A.
See details and how to joinNCT05759923 · EU 2024-510836-31-00
Phase 2Taking people
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Where
Gdynia, Siedlce
Age
18 years and over
People
270 worldwide
Run by
Corcept Therapeutics
See details and how to joinNCT06906341
Phase 2Taking people
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Where
Bialystok, Siedlce
Age
18 years and over
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT06682988 · EU 2024-517184-23-00
Phase 2Taking people
A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors
Where
Cracow, Gdynia
Age
18 years and over
People
101 worldwide
Run by
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.
See details and how to joinNCT05642780 · EU 2022-502654-14-00